Published in Nat Protoc on January 01, 2006
The Cardiac TBX5 Interactome Reveals a Chromatin Remodeling Network Essential for Cardiac Septation. Dev Cell (2016) 1.45
Cell-surface proteomics identifies lineage-specific markers of embryo-derived stem cells. Dev Cell (2012) 1.37
Surface-exposed proteins of Ehrlichia chaffeensis. Infect Immun (2007) 1.26
A mass spectrometric-derived cell surface protein atlas. PLoS One (2015) 1.04
Proteomic profiling of cardiac tissue by isolation of nuclei tagged in specific cell types (INTACT). Development (2014) 0.92
Direct detection of biotinylated proteins by mass spectrometry. J Proteome Res (2014) 0.87
Quantity and accessibility for specific targeting of receptors in tumours. Sci Rep (2014) 0.84
Differential axial localization along the mouse brain vascular tree of luminal sodium-dependent glutamine transporters Snat1 and Snat3. J Cereb Blood Flow Metab (2011) 0.83
The proteomics big challenge for biomarkers and new drug-targets discovery. Int J Mol Sci (2012) 0.79
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer (2002) 1.53
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol (2012) 1.46
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood (2008) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Encoded self-assembling chemical libraries. Nat Biotechnol (2004) 1.40
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer (2008) 1.36
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res (2007) 1.26
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A (2008) 1.18
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res (2007) 1.14
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol (2002) 1.12
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res (2010) 1.10
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2007) 1.10
Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta (2007) 1.08
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res (2014) 1.01
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res (2003) 1.01
Molecular targeting of angiogenesis. Biochim Biophys Acta (2004) 1.00
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med (2006) 1.00
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett (2009) 0.99
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther (2007) 0.99
20 years of DNA-encoded chemical libraries. Chem Commun (Camb) (2011) 0.99
Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res (2004) 0.99
In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood (2009) 0.99
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel (2006) 0.98
Lead discovery by DNA-encoded chemical libraries. Drug Discov Today (2007) 0.98
Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res (2006) 0.96
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res (2011) 0.96
Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl (2013) 0.96
Selection of streptavidin binders from a DNA-encoded chemical library. Bioconjug Chem (2006) 0.95
Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc (2012) 0.95
A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2008) 0.95
Sequence determinants of a microtubule tip localization signal (MtLS). J Biol Chem (2012) 0.95
Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics (2005) 0.95
Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem (2002) 0.94
Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds. ACS Chem Biol (2011) 0.93
New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem (2009) 0.93
Design and synthesis of a novel DNA-encoded chemical library using Diels-Alder cycloadditions. Bioorg Med Chem Lett (2008) 0.93
Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel (2007) 0.92
The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res (2012) 0.92
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res (2009) 0.92
Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope (2003) 0.92
Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J (2008) 0.92
Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis (2009) 0.92
A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl (2014) 0.92
Antibody-based vascular tumor targeting. Recent Results Cancer Res (2010) 0.92
Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res (2009) 0.92
A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl (2011) 0.91
DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors. Bioconjug Chem (2008) 0.91
Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res (2012) 0.90
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res (2014) 0.90
An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer (2006) 0.90
Affinity-capture reagents for protein arrays. Trends Biotechnol (2002) 0.89
Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol Head Neck Surg (2007) 0.89
An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys (2002) 0.88
Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs (2012) 0.88
A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem (2006) 0.88
Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). Nucl Med Biol (2006) 0.88
On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides. Chem Biol (2006) 0.87
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol (2012) 0.87
Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer (2006) 0.87
A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res (2009) 0.87
Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library. Angew Chem Int Ed Engl (2015) 0.87
Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des (2004) 0.87
A comparison of different biotinylation reagents, tryptic digestion procedures, and mass spectrometric techniques for 2-D peptide mapping of membrane proteins. Proteomics (2005) 0.86
Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer (2008) 0.86
Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp Cell Res (2009) 0.86
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med (2012) 0.86
Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis. Int J Cardiol (2013) 0.86
High-throughput sequencing for the identification of binding molecules from DNA-encoded chemical libraries. Bioorg Med Chem Lett (2010) 0.85
Ligand-based vascular targeting of disease. ChemMedChem (2007) 0.85
A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol (2010) 0.85
Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med (2007) 0.85
Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study. Proteomics (2003) 0.85
Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library. Bioconjug Chem (2010) 0.84
Covalent DNA display as a novel tool for directed evolution of proteins in vitro. Protein Eng Des Sel (2004) 0.84